US-FDA Filing

被引：0
|
作者：
Geetha, L. [1 ]
Swarnakumari, P. [1 ]
机构：
[1] MNR Coll Pharm, Sangareddy 502294, AP, India
来源：
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2009年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [1] US-FDA Approved Drugs in 2020 and 2021: A Review
    Passi, Indu
    Salwan, Sushant
    Kumar, Bhupinder
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (12) : 1273 - 1297
  • [2] Can the US-FDA really speed up in approving new drugs?
    Senn, HJ
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (05) : 749 - 749
  • [3] (Bio)manufactured Solutions for Treatment of Bone Defects with an Emphasis on US-FDA Regulatory Science Perspective
    Ghelich, Pejman
    Kazemzadeh-Narbat, Mehdi
    Hassani Najafabadi, Alireza
    Samandari, Mohamadmahdi
    Memic, Adnan
    Tamayol, Ali
    ADVANCED NANOBIOMED RESEARCH, 2022, 2 (04):
  • [4] European Community and US-FDA Approval of Recombinant Human Antithrombin Produced in Genetically Altered Goats
    Adiguzel, Cafer
    Iqbal, Omer
    Demir, Muzaffer
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 (06) : 645 - 651
  • [5] Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission
    Cardot, J. -M.
    Garcia-Arieta, A.
    Paixao, P.
    Tasevska, I.
    Davit, B.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 111 : 399 - 408
  • [6] Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis
    Raghuvanshi, Sourabh
    Rahman, Mohammad Akhlaquer
    Posa, Mahesh Kumar
    Kumar, Anoop
    CURRENT DRUG SAFETY, 2024, 19 (03) : 395 - 401
  • [7] Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA
    Grewal, Udhayvir Singh
    Thakre, Anuj
    ENDOCRINE, 2024, 86 (03) : 1192 - 1193
  • [8] FDA reconsiders electronic filing
    Mullin, R
    CHEMICAL & ENGINEERING NEWS, 2003, 81 (10) : 25 - 26
  • [9] PATIENTS LEVEL COST OF TREATING ADVERSE EVENTS IN ALZHEIMER'S DISEASE FOR US-FDA APPROVED TREATMENTS
    Sanogo, V
    Almutairi, R.
    Diaby, K.
    VALUE IN HEALTH, 2023, 26 (12) : S179 - S180
  • [10] Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality
    Tamatam, Rekha
    Shin, Dongyun
    PHARMACEUTICALS, 2023, 16 (03)
12345